Hook & thesis
Acme United Corporation has quietly re-rated higher year-to-date, but the move leaves the stock trading at modest multiples given its cash generation and recent strategic bolt-on acquisition. At $42.50 the business still trades with an enterprise value of roughly $177.4 million and an EV/EBITDA near 8.4x, which, for a stable, cash-generative supplier of cutting, measuring and first-aid products, reads as reasonable to inexpensive.
Our thesis: the combination of steady margins, a small but accretive tuck-in (My Medic), a regular quarterly dividend, and low net leverage support a position-sized long trade. We expect upside to at least $50 over a position-hold window if Acme converts the My Medic revenue run-rate into broader distribution gains; downside is limited by conservative leverage and ongoing free cash flow.
What the company does and why the market should care
Acme United supplies cutting tools, measuring instruments and safety/first-aid products across the United States, Canada and Europe under brands including Westcott, Clauss, Camillus, First Aid Only and others. The company's mix spans consumable and durable products used by schools, offices, hardware stores and industrial customers - a diversified demand base that tends to smooth revenue volatility.
The market should care because Acme combines steady end-market exposure with a history of returning cash to shareholders (a $0.16 quarterly dividend) and a manageable balance sheet. The business model produces free cash flow - recent reported free cash flow was $7.58 million - which underpins the dividend and makes small strategic acquisitions like My Medic ($18.7 million purchase price) plausible without stretching leverage.
Key numbers that support the case
| Metric | Value |
|---|---|
| Current price | $42.50 |
| Shares outstanding | 3,808,230 |
| Market cap | $161.85M |
| Enterprise value | $177.40M |
| EV/EBITDA | ~8.4x |
| Free cash flow | $7.58M |
| Price / earnings (trailing) | ~15.6x |
| Dividend (quarterly) | $0.16 (yield ~1.5%) |
Those numbers tell a consistent story: the company produces free cash flow, pays a small dividend, and recently added a $19 million revenue-generating business (My Medic reported roughly $19 million in 2025 revenues). The acquisition was funded with $14.6 million at close and $4.1 million contingent, modest against a $177 million enterprise value.
Valuation framing
At a market cap around $161.8 million and enterprise value near $177.4 million, Acme’s multiples are conservative. The EV/EBITDA of about 8.4x and price-to-free-cash-flow near 21x (and price-to-cash-flow ~8.7x) indicate that the market is pricing the company as a low-growth, stable business rather than a high-growth multiple. Given the industry - wholesale/distribution of consumable products with recurring reorder dynamics - that multiple is reasonable and arguably discounted if Acme can expand margins modestly or grow revenue through cross-selling.
Comparative peers in specialty distribution often trade in a wide range depending on growth profiles, but for a company with low debt-to-equity (~0.18), positive return on equity (~8.66%), and a steady FCF stream, sub-9x EV/EBITDA is attractive. The stock also trades well below its 52-week high of $47.31, leaving room to recapture prior highs if execution on My Medic and margin control is satisfactory.
Technical and sentiment check
Technicals are mixed but not alarming. The 10-day SMA (~$41.85) sits below current price indicating short-term support, while the 50-day SMA (~$44.01) is above, signalling the stock has room to climb to resume a higher trend. RSI near 46 is neutral. Short interest data shows modest short interest with days-to-cover in recent readings around 4.3, rising from higher winter levels - this can add a modest squeeze risk but is not extreme. Recent short-volume data shows a material portion of daily volume being shorted on certain days, which can amplify moves but also highlights the stock’s capacity for quick swings.
Catalysts
- Integration and distribution expansion of My Medic - the acquired business generated ~ $19M in 2025 revenue; successful cross-channel distribution could drive incremental top-line growth.
- Consistent quarterly dividend (most recent payable 04/15/2026) that supports investor income case and reduces downside in sideways markets.
- Operational margin improvement - modest SG&A leverage or procurement gains could expand EBITDA and depress EV/EBITDA quickly.
- Seasonal back-to-school and consumer reopenings in Europe/Canada could lift volumes in core categories like Westcott scissors and classroom supplies.
Trade plan - actionable entry, stops, targets
Stance: Long.
Entry: $42.25 - take an initial position on a small pullback or at-the-market if momentum continues; the current trading range has established support near the low-$42s.
Stop loss: $37.00 - a break below $37 erases the recent base and pushes price well below the 2026 consolidation area; exit to limit position-level downside.
Target: $50.00 - first objective, representing a recovery above the prior 52-week high area and material multiple expansion. Consider trimming into strength; a secondary target of $55 could be set for longer-term bulls if EBITDA expansion materializes.
Suggested sizing: position-size according to your risk plan; given modest volatility and low float (~3.38M shares), avoid oversized entries that could be slippage-prone.
Horizon: position-hold (180 trading days). Expect this trade to develop over several quarters as integration outcomes from My Medic and seasonal demand manifest; stay patient and monitor margin trends and working capital turnover closely.
Risks and counterarguments
- Acquisition integration risk. My Medic was purchased for $18.7M; missteps in integrating SKUs or inventory could pressure margins and working capital, reducing the accretive impact investors expect.
- Demand cyclicality. While product mix is diversified, end markets like schools and seasonal retail can produce lumpy sales, which could compress reported EBITDA in some quarters and weigh on the stock.
- Small-cap liquidity and short squeezes. Float is limited (~3.38M) and average volume is modest; this creates the potential for outsized moves on headline news or active short positioning, increasing execution risk when buying or selling large blocks.
- Margin pressure from commodity costs or freight. If input costs or shipping spikes return, a company selling lower-margin consumables could see gross margin squeeze that is not fully offset by price increases.
- Currency and international risk. Acme operates in multiple geographies; FX swings or European demand softness could reduce reported results in USD terms.
Counterargument: critics will point out that the company is a low-growth distributor and therefore deserves low multiples; paying around 8.4x EV/EBITDA may be fair if growth stalls. That is a valid view. However, because Acme produces positive free cash flow ($7.58M) and carries light leverage (debt/equity ~0.18), the downside is somewhat cushioned versus higher-levered peers. The investment case depends on modest revenue/EBITDA durability and management execution on cross-selling My Medic into existing channels.
What would change my mind?
I would downgrade this trade if any of the following occurred: a meaningful miss in quarterly EBITDA driven by inventory write-downs or integration failures at My Medic; a sudden step-up in leverage (meaningful additional acquisition-related debt that pushes debt/equity materially higher); or if free cash flow turns negative for two consecutive quarters. Conversely, persistent margin expansion, faster-than-expected cross-sell into existing channels, or upward revisions to 2026 guidance would make me more bullish and warrant adding to the position.
Conclusion
Acme United is not a high-flying software name; it is a conservative, cash-generative, small-cap distributor that has room to appreciate if modest operational improvements and the My Medic acquisition play out. At current prices the valuation is reasonable for a low-leverage business producing free cash flow and paying a dividend. For investors willing to accept small-cap liquidity risk and execution risk on acquisitions, a disciplined long position with an entry near $42.25, a $37 stop and a $50 target over a position-hold time frame is a pragmatic way to capture upside while limiting downside exposure.
Trade plan recap: Buy at $42.25 / Stop $37.00 / Target $50.00 - Position-hold (180 trading days).